Sanibel Captiva Trust Company Inc. Has $259,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sanibel Captiva Trust Company Inc. boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 643 shares of the pharmaceutical company’s stock after buying an additional 110 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Vertex Pharmaceuticals were worth $259,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Arkadios Wealth Advisors boosted its holdings in Vertex Pharmaceuticals by 61.1% in the fourth quarter. Arkadios Wealth Advisors now owns 1,081 shares of the pharmaceutical company’s stock valued at $435,000 after acquiring an additional 410 shares during the last quarter. InTrack Investment Management Inc lifted its position in Vertex Pharmaceuticals by 49.9% during the 4th quarter. InTrack Investment Management Inc now owns 2,132 shares of the pharmaceutical company’s stock valued at $878,000 after purchasing an additional 710 shares during the period. TrueWealth Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 35.4% in the 4th quarter. TrueWealth Advisors LLC now owns 1,037 shares of the pharmaceutical company’s stock valued at $418,000 after purchasing an additional 271 shares during the last quarter. Arthur M. Cohen & Associates LLC grew its position in shares of Vertex Pharmaceuticals by 3.5% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 890 shares of the pharmaceutical company’s stock worth $358,000 after buying an additional 30 shares during the period. Finally, Brooklyn Investment Group raised its stake in shares of Vertex Pharmaceuticals by 1.8% during the fourth quarter. Brooklyn Investment Group now owns 1,906 shares of the pharmaceutical company’s stock worth $768,000 after buying an additional 33 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

VRTX has been the topic of a number of recent research reports. UBS Group raised their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Citigroup began coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.2 %

NASDAQ VRTX opened at $422.00 on Monday. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $108.68 billion, a PE ratio of -212.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The business’s 50-day moving average price is $440.94 and its two-hundred day moving average price is $466.09.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.67 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.